VIR-7831
Jump to navigation
Jump to search
Indications
- treatment of outpatients with COVID-19 (adults and adolescents >= 12 years. >= 40 kg) at high risk of hospitalization or death
Contraindications
- not yet FDA-approved
Dosage
- 500 mg once by intravenous infusion
- IM administration in trial
Mechanism of action
- potential to both block viral entry into healthy cells & clear infected cells
- the antibody binds to an epitope on SARS-CoV2 that is shared with SARS-CoV-1
- epitope may or may not be spike protein (ref[1] does not say)
- engineered to potentially enhance virus-specific T cell function
Notes
- GlaxoSmithKline and Vir Biotechnology are seeking emergency use authorization
- trial was stopped early "due to evidence of profound efficacy"
More general terms
References
- ↑ 1.0 1.1 GSK News Release. Mearch 26, 2021 GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19. https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19/
- ↑ Reuters Staff GSK and Vir Seek Emergency Use of COVID-19 Therapy in United States. Medscape - Mar 26, 2021. https://www.medscape.com/viewarticle/948182